Actionnariat et activité des initiés pour Arbutus Biopharma Corp (ABUS): transactions des initiés, déclarations de trading du Sénat et de la Chambre américaine et actions en circulation. Suivez comment dirigeants et politiciens négocient le titre.
Prix
| Prix | $5.05 |
| Capitalisation | $998M |
| Bourse | NASDAQ |
| Pays | US |
Bilan (10 ans)
| Année | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Trésorerie | $23.4M | $54.3M | $36.9M | $31.8M | $52.3M | $109.3M | $30.8M | $26.3M | $36.3M | $18.0M |
| Placements à Court Terme | $107.1M | $72.1M | $87.7M | $59.0M | $71.0M | $46.0M | $116.1M | $99.7M | $86.3M | $73.5M |
| Créances | $694000 | $870000 | $1.4M | $1.2M | $1.3M | $899000 | $1.4M | $1.8M | $2.4M | $1.7M |
| Stocks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Actifs Courants | $132.6M | $129.4M | $129.2M | $93.8M | $127.7M | $160.7M | $151.1M | $132.0M | $127.3M | $94.5M |
| Immobilisations Corporelles | $6.9M | $12.2M | $10.1M | $11.4M | $9.3M | $8.1M | $6.8M | $6.1M | $4.4M | $32000 |
| Goodwill | $24.4M | $24.4M | $22.5M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Actifs Incorporels | $99.4M | $58.6M | $43.8M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Actifs Totaux | $275.9M | $237.2M | $227.9M | $105.5M | $137.1M | $204.5M | $195.4M | $144.4M | $131.7M | $94.6M |
| Dettes Fournisseurs | $3.2M | $2.0M | $3.2M | $2.4M | $3.0M | $3.2M | $3.5M | $3.2M | $2.3M | $1.2M |
| Dette à Court Terme | 0 | 0 | 0 | 0 | 0 | $383000 | $372000 | 0 | $483000 | $547000 |
| Passifs Courants | $10.6M | $11.9M | $11.2M | $7.8M | $9.5M | $11.2M | $32.9M | $22.5M | $15.6M | $6.0M |
| Dette à Long Terme | $12.0M | $12.0M | 0 | 0 | $19.6M | $16.3M | $10.4M | $7.0M | $4.8M | $3.4M |
| Passifs Totaux | $72.9M | $54.7M | $27.7M | $32.8M | $35.1M | $35.0M | $58.6M | $38.4M | $34.3M | $18.0M |
| Réserves | -$651.1M | -$738.1M | -$805.2M | -$970.1M | -$1.05B | -$1.13B | -$1.20B | -$1.28B | -$1.35B | -$1.38B |
| Capitaux Propres | $203.0M | $182.5M | $200.2M | $72.7M | $102.0M | $169.4M | $136.9M | $106.0M | $97.4M | $76.6M |
| Dette Totale | $12.0M | $12.0M | 0 | $3.4M | $22.5M | $18.9M | $12.6M | $8.7M | $6.1M | $4.2M |
| Dette Nette | -$118.5M | -$114.4M | -$124.6M | -$87.5M | -$100.7M | -$136.4M | -$134.4M | -$117.3M | -$116.5M | -$87.3M |
| Fonds de Roulement | $122.0M | $117.5M | $118.0M | $86.0M | $118.2M | $149.4M | $118.3M | $109.5M | $111.7M | $88.5M |
Santé financière
| Dette / Capitaux propres | 0.01 |
| Ratio de liquidité | 81.42 |
| Piotroski F-Score | 4 |
| Altman Z-Score | 10.56 |
Rentabilité
| Rentabilité des capitaux propres | 90.98% |
| Rentabilité du capital investi | 54.29% |
| Rentabilité des actifs | 55.85% |
| Marge brute | 99.98% |
| Marge opérationnelle | 81.01% |
| Marge nette | 84.23% |
Entreprises liées: BCAX · EYPT · GHRS · KURA · NBTX · PROK · SEPN
Explorer le secteur: Healthcare · Biotechnology
Plus de sections de ABUS: Vue d'ensemble · Financiers · Valorisation · Statistiques · Estimations · Technique · Actualités · Événements
Découvrir plus: Radar — signaux d'actions sous-évaluées · Académie d'Investissement — apprenez à analyser les actions